ReviewPharmaceutical nanotechnology2025
Quercetin Nano-formulations as a Potential Approach for Skin Cancer.
Review in Pharmaceutical nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Plant-Derived Compounds as Potential Sensitizers to Immunotherapy in Melanoma.International journal of molecular sciences · 2026Review
- Reactive oxygen species in skin diseases: pathogenic mechanisms and nanomaterial-based therapeutic strategies.Frontiers in bioengineering and biotechnology · 2026Review
- Interdisciplinarity traditional Chinese medicine microneedles in skin disease treatment: Recent advances and challenges.Bioactive materials · 2026Review
- Synergistic Interactions Between Natural Phenolic Compounds and Antibiotics Against Multidrug-ResistantMicroorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin, a natural flavonoid, is well-proven for anticancer properties in a variety of cancers. Quercetin's anticancer action is driven by its anti-inflammatory and antioxidant properties. It inhibits pro-inflammatory cytokines (e.g., TNF-α, IL-6) and suppresses NF-κB and COX-2, reducing tumor growth. Its antioxidant activity neutralizes reactive oxygen species (ROS), preventing oxidative damage that can lead to cancer. However, quercetin faces challenges such as poor solubility, bioavailability, instability, low skin penetration, rapid metabolism, and potential systemic toxicity at high doses, which limit its therapeutic application. Nanocarrier systems such as liposomes, polymeric nanoparticles (PLGA-based), solid lipid nanoparticles (SLNs), and nanoemulsions have been developed to address these issues. These formulations enhance quercetin's penetration, stability, and bioavailability, improving its effectiveness against skin cancers by promoting controlled release and targeted delivery. Nanocarriers offer a promising solution to overcome these limitations and enhance its anticancer potential.
Indexed as
Identifiers
39660525What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.